![[Evaluation of Healthcare Professionals in Contact with Patients Diagnosed with COVID-19 Detected Outside of the Pandemic Service in our Hospital]](https://www.des-testbed.net/grd/uploads/2021/04/photo_2020-12-09_23-38-06.jpg)
The “Coronavirus Illness 19 (COVID-19)” brought on by “Extreme Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)” remains to be energetic all around the world as a pandemia. It’s reported that at the very least 7000 well being care employees (HCW) had misplaced their lives as a consequence of COVID-19 from the start of the pandemia until September 2020 on the planet. In our nation between the dates, March 11, 2020 which the primary case was reported, and September 1, 2020, the date which our examine has been finalized, 7428 HCW have been contaminated by SARS-CoV-2, and 52 of them have been deceased.
On this examine, it was aimed to guage the contact and sickness of healthcare employees working outdoors of the pandemic clinics in our hospital and to look at the doable transmission routes and illness prognoses. Healthcare employees who have been working outdoors the pandemic service between March 11, 2020 and September 1, 2020 and who had a particular prognosis of COVID-19 and all hospital employees who had contacted with these folks, and HCW who had contact with sufferers recognized with COVID-19 whereas receiving inpatient therapy in providers aside from the pandemic service was evaluated and categorised as low, medium and excessive threat in line with the chance scoring outlined within the printed “Ministry of Well being COVID-19 Pointers”.
Healthcare employees who have been evaluated as contacted have been questioned intimately relating to the usage of private protecting tools (PPE) on the time of contact, particularly suitability of the masks, contact time and form and all the info have been recorded. A complete of 53 index instances (40 HCW and 13 inpatients recognized as COVID-19) have been detected through the examine interval. The variety of HCW contacted with these index instances was 672. In our examine, we examined the info of 40 index instances and 672 contacted HCW (whole of 712 HCW). Solely Three of 40 index instances (7.5%) had hospital-acquired COVID-19 an infection, the opposite 37 instances have been contaminated by group sources.
COVID-19 was not detected in 94.2% of the contacted HCW through the follow-up whereas 5.8% of them had constructive PCR take a look at outcomes. Contemplating the doable manner of contamination among the many contacted HCW who developed COVID-19 through the follow-up interval, it was decided that 13.1% of the instances have been a results of taken care of sufferers, 86.9% of the instances have been a results of being in hospital social environments (consuming tea, smoking, consuming, chatting in the identical room with out private precautions) and within the days after the contact, it was within the type of contact with healthcare personnel recognized with COVID-19.
When the contacted HCW have been questioned about utilizing correct masks on the time of contact, we decided that 93.3% of them used masks throughout affected person caring procedures, nonetheless, solely 48.9% used masks once they have been in social areas (p<0.001). Healthcare employees face an unprecedented threat of occupational illness and demise because of the COVID-19 pandemic. Nonetheless, it is usually noticed that extended pandemia interval induced well being employees to ignore rigorous an infection management precautions in social areas of hospitals which they observe inpatient care though this has proven to be the commonest manner of contamination.
![[Evaluation of Healthcare Professionals in Contact with Patients Diagnosed with COVID-19 Detected Outside of the Pandemic Service in our Hospital]](https://www.des-testbed.net/grd/uploads/2021/04/photo_2020-12-09_23-38-06-146x300.jpg)
RANDGAN: Randomized generative adversarial community for detection of COVID-19 in chest X-ray
COVID-19 unfold throughout the globe at an immense fee and has left healthcare programs incapacitated to diagnose and take a look at sufferers on the wanted fee. Research have proven promising outcomes for detection of COVID-19 from viral bacterial pneumonia in chest X-rays. Automation of COVID-19 take a look ating utilizing medical photographs can velocity up the take a look ating technique of sufferers the place well being care programs lack ample numbers of the reverse-transcription polymerase chain response checks. Supervised deep studying fashions corresponding to convolutional neural networks want sufficient labeled information for all lessons to accurately study the duty of detection.
Gathering labeled information is a cumbersome job and requires time and assets which may additional pressure well being care programs and radiologists on the early phases of a pandemic corresponding to COVID-19. On this examine, we suggest a randomized generative adversarial community that detects photographs of an unknown class from identified and labelled lessons (Regular and Viral Pneumonia) with out the necessity for labels and coaching information from the unknown class of photographs. We used the most important publicly out there COVID-19 chest X-ray dataset, COVIDx, which is comprised of Regular, Pneumonia, and COVID-19 photographs from a number of public databases.
On this work, we use switch studying to phase the lungs within the COVIDx dataset. Subsequent, we present why segmentation of the area of curiosity (lungs) is significant to accurately study the duty of classification, particularly in datasets that include photographs from completely different assets as it’s the case for the COVIDx dataset. Lastly, we present improved leads to detection of COVID-19 instances utilizing our generative mannequin in comparison with standard generative adversarial networks for anomaly detection in medical photographs, enhancing the realm below the ROC curve from 0.71 to 0.77.
Alpha-bungarotoxin, CF405s |
|||
| 00002-100ug | Biotium | 100uG | EUR 193.2 |
|
Description: Minimum order quantity: 1 unit of 100uG |
|||
Alpha-bungarotoxin, CF680r |
|||
| 9-00003 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Alpha-bungarotoxin, CF680r |
|||
| 9-00003 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 100uG |
|||
Alpha-bungarotoxin, CF640r |
|||
| 9-00004 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Alpha-bungarotoxin, CF640r |
|||
| 9-00004 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 100uG |
|||
Alpha-bungarotoxin, CF488a |
|||
| 9-00005 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Alpha-bungarotoxin CF488a |
|||
| 9-00005 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 100uG |
|||
Alpha-bungarotoxin, CF568 |
|||
| 9-00006 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Alpha-bungarotoxin, CF568 |
|||
| 9-00006 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 100uG |
|||
Alpha-bungarotoxin, CF594 |
|||
| 9-00007 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Alpha-bungarotoxin CF594 |
|||
| 9-00007 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 100uG |
|||
Alpha-bungarotoxin, CF633 |
|||
| 9-00009 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Alpha-bungarotoxin, CF633 |
|||
| 9-00009 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 100uG |
|||
Alpha-bungarotoxin |
|||
| 00010-1 | Biotium | 1MG | EUR 201.6 |
|
Description: Minimum order quantity: 1 unit of 1MG |
|||
Fluorescein-Alpha-bungarotoxin |
|||
| 00011 | Biotium | 500uG | EUR 440.4 |
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Tetramethylrhodamine-Alpha-bungarotoxin |
|||
| 00012 | Biotium | 500uG | EUR 459.6 |
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Fluorescein-alpha-bungarotoxin: (10x50ug) |
|||
| 00013 | Biotium | 10ST | EUR 500.4 |
|
Description: Minimum order quantity: 1 unit of 10ST |
|||
Tetramethylrhodamine-alpha-bungarotoxin: (10x50ug) |
|||
| 00014 | Biotium | 10ST | EUR 559.2 |
|
Description: Minimum order quantity: 1 unit of 10ST |
|||
Sulforhodamine 101-a-bungarotoxin (Texas Red--a-bungarotoxin): (500ug) |
|||
| 00015 | Biotium | 500uG | EUR 559.2 |
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Sulforhodamine 101-a-bungarotoxin (Texas Red--a-bungarotoxin): (10x50ug) |
|||
| 00016 | Biotium | 10ST | EUR 627.6 |
|
Description: Minimum order quantity: 1 unit of 10ST |
|||
Biotin-xx-a-bungarotoxin |
|||
| 00017 | Biotium | 500uG | EUR 519.6 |
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Alpha-Bungarotoxin, CF555 conjugate |
|||
| 9-00018 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Alpha-Bungarotoxin, CF555 conjugate |
|||
| 9-00018 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Biotin-cAMP, diisopropylethylammonium salt: |
|||
| 00020 | Biotium | 1MG | EUR 376.8 |
|
Description: Minimum order quantity: 1 unit of 1MG |
|||
Biotin-cAMP, diisopropylethylammonium salt: (20x50ug) |
|||
| 00020-1 | Biotium | 20ST | EUR 501.6 |
|
Description: Minimum order quantity: 1 unit of 20ST |
|||
Biotin-cGMP, diisopropylethylammonium salt: |
|||
| 00021 | Biotium | 1MG | EUR 412.8 |
|
Description: Minimum order quantity: 1 unit of 1MG |
|||
Biotin-cGMP, diisopropylethylammonium salt: (20x50ug) |
|||
| 00021-1 | Biotium | 20ST | EUR 537.6 |
|
Description: Minimum order quantity: 1 unit of 20ST |
|||
Cyanine 644-cAMP: |
|||
| 00022 | Biotium | 1MG | EUR 589.2 |
|
Description: Minimum order quantity: 1 unit of 1MG |
|||
Cyanine 644-cAMP: (20x50ug) |
|||
| 00022-1 | Biotium | 20ST | EUR 750 |
|
Description: Minimum order quantity: 1 unit of 20ST |
|||
Fluorescein Methotrexate, triammonium salt: |
|||
| 00023 | Biotium | 1MG | EUR 337.2 |
|
Description: Minimum order quantity: 1 unit of 1MG |
|||
Staurosporine |
|||
| 00025 | Biotium | 100uG | EUR 166.8 |
|
Description: Minimum order quantity: 1 unit of 100uG |
|||
Alpha-bungarotoxin, CF543 |
|||
| 00026 | Biotium | 500uG | EUR 592.8 |
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Rhodamine phalloidin 300u |
|||
| 00027 | Biotium | 300 | EUR 414 |
|
Description: Minimum order quantity: 1 unit of 300 |
|||
Biotin-xx-phalloidin |
|||
| 00028 | Biotium | 100U | EUR 513.6 |
|
Description: Minimum order quantity: 1 unit of 100U |
|||
Fluorescein-phalloidin |
|||
| 00030 | Biotium | 300U | EUR 414 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Rhodamine 110 phalloidin |
|||
| 00032 | Biotium | 300ST | EUR 414 |
|
Description: Minimum order quantity: 1 unit of 300ST |
|||
Sulforhodamine 101 (Texas-Red) Phalloidin |
|||
| 00033 | Biotium | 300EU | EUR 414 |
|
Description: Minimum order quantity: 1 unit of 300EU |
|||
Phalloidin, CF405M |
|||
| 00034 | Biotium | 300U | EUR 530.4 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF405M |
|||
| 00034-T | Biotium | 50U | EUR 159.6 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
CF488A-cAMP |
|||
| 00036 | Biotium | 100ug | EUR 206.4 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
CF640R-cAMP |
|||
| 00037 | Biotium | 100ug | EUR 206.4 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Phalloidin, CF555 |
|||
| 00040 | Biotium | 300U | EUR 530.4 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF555 |
|||
| 00040-T | Biotium | 50U | EUR 159.6 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF647 |
|||
| 00041 | Biotium | 300U | EUR 530.4 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF647 |
|||
| 00041-T | Biotium | 50U | EUR 159.6 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF488A |
|||
| 00042 | Biotium | 300U | EUR 530.4 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF488A |
|||
| 00042-T | Biotium | 50U | EUR 159.6 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF543 |
|||
| 00043 | Biotium | 300U | EUR 530.4 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF543 |
|||
| 00043-T | Biotium | 50U | EUR 159.6 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF568 |
|||
| 00044 | Biotium | 300U | EUR 530.4 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF568 |
|||
| 00044-T | Biotium | 50U | EUR 159.6 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF594 |
|||
| 00045 | Biotium | 300U | EUR 530.4 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF594 |
|||
| 00045-T | Biotium | 50U | EUR 159.6 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF633 |
|||
| 00046 | Biotium | 300U | EUR 530.4 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF633 |
|||
| 00046-T | Biotium | 50U | EUR 159.6 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF660R |
|||
| 00047 | Biotium | 300U | EUR 530.4 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF660R |
|||
| 00047-T | Biotium | 50U | EUR 159.6 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF680R |
|||
| 00048 | Biotium | 300U | EUR 559.2 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF680R |
|||
| 00048-T | Biotium | 50U | EUR 159.6 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF350 |
|||
| 00049 | Biotium | 300U | EUR 530.4 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF350 |
|||
| 00049-T | Biotium | 50U | EUR 159.6 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF640R |
|||
| 00050 | Biotium | 300U | EUR 530.4 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF640R |
|||
| 00050-T | Biotium | 50U | EUR 159.6 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF532 |
|||
| 00051 | Biotium | 300U | EUR 530.4 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF532 |
|||
| 00051-T | Biotium | 50U | EUR 159.6 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF660C |
|||
| 00052 | Biotium | 300U | EUR 530.4 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF660C |
|||
| 00052-T | Biotium | 50U | EUR 159.6 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF680 |
|||
| 00053 | Biotium | 300U | EUR 559.2 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF680 |
|||
| 00053-T | Biotium | 50U | EUR 176.4 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF430 |
|||
| 00054 | Biotium | 300U | EUR 538.8 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF430 |
|||
| 00054-T | Biotium | 50U | EUR 166.8 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF440 |
|||
| 00055 | Biotium | 300U | EUR 538.8 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF440 |
|||
| 00055-T | Biotium | 50U | EUR 166.8 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Cholera Toxin Subunit B, CF488A conjugate |
|||
| 00070 | Biotium | 100ug | EUR 313.2 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Cholera Toxin Subunit B, CF568 conjugate |
|||
| 00071 | Biotium | 100ug | EUR 313.2 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Cholera Toxin Subunit B, CF594 conjugate |
|||
| 00072 | Biotium | 100ug | EUR 313.2 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Cholera Toxin Subunit B, CF640R conjugate |
|||
| 00073 | Biotium | 100ug | EUR 316.8 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Cholera Toxin Subunit B, CF532 conjugate |
|||
| 00074 | Biotium | 100ug | EUR 316.8 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Cholera Toxin Subunit B, CF543 conjugate |
|||
| 00075 | Biotium | 100ug | EUR 316.8 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Cholera Toxin Subunit B, CF620R conjugate |
|||
| 00076 | Biotium | 100ug | EUR 316.8 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Cholera Toxin Subunit B, CF633 conjugate |
|||
| 00077 | Biotium | 100ug | EUR 316.8 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Cholera Toxin Subunit B, CF660R conjugate |
|||
| 00078 | Biotium | 100ug | EUR 316.8 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Cholera Toxin Subunit B, CF680R conjugate |
|||
| 00079 | Biotium | 100ug | EUR 338.4 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Human Transferrin, CF488A conjugate |
|||
| 00081 | Biotium | 1mg | EUR 178.8 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
Human Transferrin, CF543 conjugate |
|||
| 00082 | Biotium | 1mg | EUR 178.8 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
Human Transferrin, CF568 conjugate |
|||
| 00083 | Biotium | 1mg | EUR 178.8 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
Human Transferrin, CF594 conjugate |
|||
| 00084 | Biotium | 1mg | EUR 178.8 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
Human Transferrin, CF640R conjugate |
|||
| 00085 | Biotium | 1mg | EUR 178.8 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
Human Transferrin, CF680R conjugate |
|||
| 00086 | Biotium | 1mg | EUR 178.8 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
Human Transferrin, CF750 conjugate |
|||
| 00087 | Biotium | 1mg | EUR 186 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
HIV-1 tat recombinant antigen |
|||
| 00110-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HIV-1 tat recombinant antigen full length 15 kDa |
|||
HIV-1 tat recombinant antigen |
|||
| 00110-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HIV-1 tat recombinant antigen full length 15 kDa |
|||
HIV-1 GAG P24 Recombinant Antigen |
|||
| 00111-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa |
|||
HIV-1 GAG P24 Recombinant Antigen |
|||
| 00111-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa |
|||
HIV-1 nef recombinant antigen |
|||
| 00112-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa |
|||
HIV-1 nef recombinant antigen |
|||
| 00112-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa |
|||
HIV-1 env gp41 recombinant antigen |
|||
| 00113-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa |
|||
HIV-1 env gp41 recombinant antigen |
|||
| 00113-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa |
|||
HIV-2 GP 36 Recombinant Antigen |
|||
| 00114-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HIV -2 env gp36 recombinant antigen a.a 390 to a.a 702 of the HIV-2 env region 34 kDa |
|||
HIV-2 GP 36 Recombinant Antigen |
|||
| 00114-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HIV -2 env gp36 recombinant antigen a.a 390 to a.a 702 of the HIV-2 env region 34 kDa |
|||
HCV core recombinant antigen |
|||
| 00115-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa |
|||
HCV core recombinant antigen |
|||
| 00115-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa |
|||
HCV core recombinant antigen, Biotin conjugate |
|||
| 00115-V-B-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Biotin conjugate. |
|||
HCV core recombinant antigen, Biotin conjugate |
|||
| 00115-V-B-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Biotin conjugate. |
|||
HCV core recombinant antigen, FITC conjugate |
|||
| 00115-V-F-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Fluorescein conjugate. |
|||
HCV core recombinant antigen, FITC conjugate |
|||
| 00115-V-F-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Fluorescein conjugate. |
|||
HCV core recombinant antigen, Rhodamine |
|||
| 00115-V-R-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa . Rhodamine conjugate. |
|||
HCV core recombinant antigen, Rhodamine |
|||
| 00115-V-R-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa . Rhodamine conjugate. |
|||
HCV NS4 recombinant antigen NS4a+b |
|||
| 00116-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. |
|||
HCV NS4 recombinant antigen NS4a+b |
|||
| 00116-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. |
|||
HCV NS4 recombinant antigen NS4a+b, Biotin |
|||
| 00116-V-B-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Biotin conjugate. |
|||
HCV NS4 recombinant antigen NS4a+b, Biotin |
|||
| 00116-V-B-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Biotin conjugate. |
|||
HCV NS4 recombinant antigen NS4a+b, FITC |
|||
| 00116-V-F-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Fluorescein conjugate. |
|||
HCV NS4 recombinant antigen NS4a+b, FITC |
|||
| 00116-V-F-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Fluorescein conjugate. |
|||
HCV NS4 recombinant antigen NS4a+b, Rhodamine |
|||
| 00116-V-R-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Rhodamine conjugate. |
|||
HCV NS4 recombinant antigen NS4a+b, Rhodamine |
|||
| 00116-V-R-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Rhodamine conjugate. |
|||
HCV NS3 recombinant antigen |
|||
| 00117-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HCV NS3 recombinant antigen a.a 1400 to a.a 1643 of HCV polyprotein 22 kDa |
|||
HCV NS3 recombinant antigen |
|||
| 00117-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HCV NS3 recombinant antigen a.a 1400 to a.a 1643 of HCV polyprotein 22 kDa |
|||
HBV core recombinant antigen |
|||
| 00120-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 183 of HBV core antigen 18 kDa |
|||
HBV core recombinant antigen |
|||
| 00120-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 183 of HBV core antigen 18 kDa |
|||
HBV core recombinant antigen, Delta |
|||
| 00121-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 144 of HBV core antigen 16 kDa |
|||
HBV core recombinant antigen, Delta |
|||
| 00121-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 144 of HBV core antigen 16 kDa |
|||
HBV surface recombinant antigen HBsAg |
|||
| 00122-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant |
|||
HBV surface recombinant antigen HBsAg |
|||
| 00122-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant |
|||
HBV surface recombinant antigen HBsAg antigen |
|||
| 00123-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant High purity |
|||
HBV surface recombinant antigen HBsAg antigen |
|||
| 00123-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant High purity |
|||
HBV surface recombinant antigen HBsAg antigen |
|||
| 00124-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HBV surface recombinant antigen HBsAg antigen 31 kDa E. coli recombinant |
|||
HBV surface recombinant antigen HBsAg antigen |
|||
| 00124-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HBV surface recombinant antigen HBsAg antigen 31 kDa E. coli recombinant |
|||
HEV (Birma) ORF2 recombinant antigen |
|||
| 00131-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HEV (Birma) ORF2 recombinant antigen a.a. 633 to a.a 659. |
|||
HEV (Birma) ORF2 recombinant antigen |
|||
| 00131-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HEV (Birma) ORF2 recombinant antigen a.a. 633 to a.a 659. |
|||
HEV (Birma) ORF2 recombinant antigen |
|||
| 00132-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HEV (Birma) ORF2 recombinant antigen a.a. 403 to a.a 461. |
|||
HEV (Birma) ORF2 recombinant antigen |
|||
| 00132-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HEV (Birma) ORF2 recombinant antigen a.a. 403 to a.a 461. |
|||
AA 403-461 HEV Birma ORF2 Recombinant Antigen |
|||
| 00133-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HEV (Birma) ORF2 recombinant antigen a.a. 92 to a.a 123. |
|||
AA 403-461 HEV Birma ORF2 Recombinant Antigen |
|||
| 00133-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HEV (Birma) ORF2 recombinant antigen a.a. 92 to a.a 123. |
|||
T, Pallidum recombinant antigen p15 |
|||
| 00141-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: T. Pallidum recombinant antigen p15 (full length) |
|||
T, Pallidum recombinant antigen p15 |
|||
| 00141-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: T. Pallidum recombinant antigen p15 (full length) |
|||
T, Pallidum recombinant antigen p17 |
|||
| 00142-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: T. Pallidum recombinant antigen p17 (full length) |
|||
T, Pallidum recombinant antigen p17 |
|||
| 00142-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: T. Pallidum recombinant antigen p17 (full length) |
|||
T, Pallidum recombinant antigen p45 |
|||
| 00143-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: T. Pallidum recombinant antigen p45 (full length) |
|||
T, Pallidum recombinant antigen p45 |
|||
| 00143-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: T. Pallidum recombinant antigen p45 (full length) |
|||
T, pallidum recombinant antigen TmpA |
|||
| 00144-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: T. Pallidum recombinant antigen TmpA (full length) |
|||
T, pallidum recombinant antigen TmpA |
|||
| 00144-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: T. Pallidum recombinant antigen TmpA (full length) |
|||
HCV core 2-119aa recombinant antigen |
|||
| 00150-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HCV core 2-119aa recombinant antigen. Genotypes available: 1a, 1b, 2a, 2b, 3a, 3b, 3/10, 4, 5, 6a |
|||
HCV core 2-119aa recombinant antigen |
|||
| 00150-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HCV core 2-119aa recombinant antigen. Genotypes available: 1a, 1b, 2a, 2b, 3a, 3b, 3/10, 4, 5, 6a |
|||
HCV Core 24 Antigen |
|||
| 00151-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HCV core 24 antigen. |
|||
HCV Core 24 Antigen |
|||
| 00151-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HCV core 24 antigen. |
|||
HCV core recombinant antigen |
|||
| 00152-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HCV core recombinant antigen a.a.105-302 |
|||
HCV core recombinant antigen |
|||
| 00152-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HCV core recombinant antigen a.a.105-302 |
|||
HCV NS3 1192-1456 aa Recombinant Antigen |
|||
| 00153-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HCV NS3 1192-1456aa recombinant antigen a.a.1192-1459. Available genotypes: 1a, 1b, 2b, 2c, 5, 6a |
|||
HCV NS3 1192-1456 aa Recombinant Antigen |
|||
| 00153-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HCV NS3 1192-1456aa recombinant antigen a.a.1192-1459. Available genotypes: 1a, 1b, 2b, 2c, 5, 6a |
|||
HCV NS3 1359-1456aa antigen |
|||
| 00154-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HCV NS3 1359-1456aa antigen. The protein contains immunodominant regions (1359-1456aa). available genotypes: 1a, 1b, 2b, 3, 4, 5, 6 |
|||
HCV NS3 1359-1456aa antigen |
|||
| 00154-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HCV NS3 1359-1456aa antigen. The protein contains immunodominant regions (1359-1456aa). available genotypes: 1a, 1b, 2b, 3, 4, 5, 6 |
|||
The primary native unfold of COVID-19 in Israel was detected in March 2020. As a result of range in medical shows of COVID-19, prognosis by RT-PCR alone may miss sufferers with delicate or no signs. Serology take a look ating might higher consider the precise magnitude of the unfold of an infection within the inhabitants. That is the primary nationwide seroprevalence examine carried out in Israel. It is among the most widespread to be carried out to this point, and the most important per-country inhabitants dimension.
